Clinical Trials Using Vorinostat

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Vorinostat. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-19 of 19
  • Bortezomib, Vorinostat, and Combination Chemotherapy in Treating Infants with Newly Diagnosed Acute Lymphoblastic Leukemia

    This phase I / II trial studies the side effects and best dose of vorinostat and to see how well it works when given together with bortezomib and combination chemotherapy in treating infants (patients less than 1 year old) with newly diagnosed acute lymphoblastic leukemia. Bortezomib and vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as methotrexate, hydrocortisone, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) with bortezomib and vorinostat may be a better treatment for acute lymphoblastic leukemia.
    Location: 11 locations

  • Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors

    This phase I / II trial studies the side effects and the best dose of vorinostat when given together with etoposide and to see how well they work in treating younger patients with refractory or relapsed solid tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Etoposide is a drug used in chemotherapy that works by stopping tumor cells from dividing and causing them to die. Giving vorinostat together with etoposide may kill more tumor cells.
    Location: 9 locations

  • 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat

    This study will compare three treatment regimens containing metaiodobenzylguanidine (MIBG) and compare their effects on tumor response and associated side effects, to determine if one therapy is better than the other for people diagnosed with relapsed or persistent neuroblastoma.
    Location: 8 locations

  • Pembrolizumab and Vorinostat in Treating Patients with Advanced or Metastatic Renal or Urothelial Cell Carcinoma

    This phase I / Ib trial studies the side effects of pembrolizumab and vorinostat and how well they work in treating patients with renal or urothelial cell carcinoma that has spread to other parts of the body or usually cannot be cured or controlled with treatment. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and vorinostat may work better in treating patients with advanced or metastatic renal or urothelial cell carcinoma.
    Location: 2 locations

  • Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

    A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by maintenance therapy with DFMO in subjects with newly diagnosed high risk neuroblastoma.
    Location: 2 locations

  • Vorinostat and Hydroxychloroquine in Treating Patients with Advanced Solid Tumors

    This phase I trial studies the side effects and best dose of hydroxychloroquine when given together with vorinostat in treating patients with advanced solid tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as hydroxychloroquine, may stimulate the immune system in different ways and stop tumor cells from growing. Giving vorinostat together with hydroxychloroquine may kill more tumor cells.
    Location: 2 locations

  • Pembrolizumab and Vorinostat in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma

    This phase I trial studies the side effects and best dose of vorinostat when given together with pembrolizumab in treating patients with diffuse large B-cell lymphoma, follicular lymphoma, or Hodgkin lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as pembrolizumab block cancer growth in different ways by targeting certain cells. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vorinostat and pembrolizumab together may work better in treating patients with diffuse large B-cell lymphoma, follicular lymphoma, or Hodgkin lymphoma.
    Location: 2 locations

  • Pembrolizumab and Vorinostat in Treating Patients with Stage IV Non-small Cell Lung Cancer

    This partially randomized phase I / II trial studies the side effects of pembrolizumab when given together with vorinostat and how well they work in treating patients with stage IV non-small cell lung cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab together with vorinostat may kill more tumor cells.
    Location: Moffitt Cancer Center, Tampa, Florida

  • Lenalidomide and High-Dose Chemotherapy before Stem Cell Transplant in Treating Patients with Relapsed or Refractory, Diffuse Large B-Cell Lymphoma of the ABC Subtype

    This phase I / II trial studies the side effects and best dose of lenalidomide when given together with high-dose chemotherapy (vorinostat, gemcitabine hydrochloride, busulfan, and melphalan) followed by stem cell transplant and to see how well the regimen works in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or has not responded to treatment (refractory), and is of the activated B-cell-like (ABC) subtype. Lenalidomide may stimulate the immune system to attack cancer cells. Drugs used in chemotherapy, such as vorinostat, gemcitabine hydrochloride, busulfan, and melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining lenalidomide with this chemotherapy regimen may be an effective treatment for the ABC subtype of diffuse large B-cell lymphoma.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Vorinostat and Temsirolimus with or without Radiation Therapy in Treating Younger Patients with Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma

    This phase I trial studies the side effects and best dose of temsirolimus when given together with vorinostat and with or without radiation therapy in treating younger patients with newly diagnosed or progressive diffuse intrinsic pontine glioma, a tumor that arises from the middle portion of the brain stem. Vorinostat and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving temsirolimus and vorinostat with or without radiation therapy may be a better treatment for younger patients with diffuse intrinsic pontine glioma.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Pembrolizumab, Tamoxifen Citrate, and Vorinostat in Treating Patients with Hormone Receptor Positive Stage IV Breast Cancer

    This randomized phase II trial studies the side effects of pembrolizumab, tamoxifen citrate, and vorinostat and how well they work in treating patients with hormone receptor positive stage IV breast cancer. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Estrogen can cause the growth of breast cancer cells. Antihormone therapy, such as tamoxifen citrate, may block the use of estrogen by the tumor cells. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab, tamoxifen citrate, and vorinostat may work better in treating patients with hormone receptor positive stage IV breast cancer.
    Location: UCSF Medical Center-Mount Zion, San Francisco, California

  • Sorafenib Tosylate, Vorinostat, Gemcitabine Hydrochloride, and Radiation Therapy in Treating Patients with Pancreatic Cancer

    This phase I trial studies the side effects and best dose of sorafenib tosylate and vorinostat when given together with gemcitabine hydrochloride and radiation therapy in treating patients with pancreatic cancer. Sorafenib tosylate and vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving sorafenib tosylate, vorinostat, gemcitabine hydrochloride, and radiation therapy may be a better treatment for pancreatic cancer.
    Location: Virginia Commonwealth University / Massey Cancer Center, Richmond, Virginia

  • Vorinostat and Hydroxychloroquine or Regorafenib in Treating Patients with Refractory Metastatic Colorectal Cancer

    This randomized phase II trial studies how well vorinostat and hydroxychloroquine work compared with regorafenib in treating patients with colorectal cancer that has spread to other places in the body and does not respond to treatment. Vorinostat and regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hydroxychloroquine may suppress the immune system in different ways and stop tumor cells from growing or kill them. It is not yet known whether vorinostat and hydroxychloroquine work better than regorafenib in treating patients with refractory metastatic colorectal cancer.
    Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas

  • Fludarabine Phosphate, Clofarabine, and Busulfan with Vorinostat in Treating Patients with Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant

    This phase I trial studies the side effects and best dose of vorinostat when given together with fludarabine phosphate, clofarabine, and busulfan in treating patients with acute leukemia that is under control (remission) or has returned (relapse) undergoing donor stem cell transplant. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate, clofarabine, and busulfan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vorinostat together with fludarabine phosphate, clofarabine, and busulfan before a donor stem cell transplant may be a better treatment for patients with acute leukemia.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

    This phase I / II trial studies the side effects and best dose of vorinostat when given together with gemcitabine hydrochloride and docetaxel and to see how well it works in treating patients with soft tissue sarcoma that is metastatic or cannot be removed by surgery. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vorinostat with combination chemotherapy may kill more tumor cells.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Sorafenib, Vorinostat, and Bortezomib in Treating Patients With Acute Myeloid Leukemia

    This phase I / II trial studies the side effects and best dose of sorafenib, vorinostat, and bortezomib and to see how well it works in treating patients with acute myeloid leukemia. Sorafenib, vorinostat, and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

  • Vorinostat and Iobenguane I 131 in Treating Patients With Resistant or Relapsed Neuroblastoma

    This phase I trial studies the side effects and best dose of giving vorinostat together with iobenguane I 131 in treating patients with resistant or relapsed neuroblastoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs, such as iobenguane I 131, may carry radiation directly to tumor cells and not harm normal cells. Giving vorinostat together with iobenguane I 131 may kill more tumor cells.
    Location: 16 locations

  • Vorinostat in Treating Patients with Metastatic Melanoma of the Eye

    This phase II trial studies how well vorinostat works in treating patients with melanoma of the eye that has spread to other parts of the body. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: Memorial Sloan-Kettering Cancer Center, New York, New York

  • Temozolomide and Vorinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    The purpose of the study is to determine if temozolomide plus vorinostat in combination can control relapsed or refractory acute myeloid leukemia (AML) and determine if this combination can be safely taken. The study will look at the side effects of the temozolomide plus vorinostat in combination and whether the treatment schedule is tolerated.
    Location: See Clinical Trials.gov